Evaluating surrogate endpoints

被引：22

作者：

Hughes, MD ^{[1
]}

机构：

[1] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA

来源：

CONTROLLED CLINICAL TRIALS | 2002年 / 23卷 / 06期

关键词：

D O I：

10.1016/S0197-2456(02)00264-7

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

[No abstract available]

引用

页码：703 / 707

页数：5

共 15 条

[1]

Babiker A, 2000, AIDS RES HUM RETROV, V16, P1123

[2]

Daniels MJ, 1997, STAT MED, V16, P1965, DOI 10.1002/(SICI)1097-0258(19970915)16:17<1965::AID-SIM630>3.3.CO

[3]

2-D

[4] Survival analysis using auxiliary variables via multiple imputation, with application to AIDS clinical trial data [J].

Faucett, CL ;

Schenker, N ;

Taylor, JMG .

BIOMETRICS, 2002, 58 (01) :37-47

[5]

Flandre P, 1999, STAT MED, V18, P107, DOI 10.1002/(SICI)1097-0258(19990115)18:1<107::AID-SIM965>3.3.CO

[6]

2-G

[7] SURROGATE AND AUXILIARY END-POINTS IN CLINICAL-TRIALS, WITH POTENTIAL APPLICATIONS IN CANCER AND AIDS RESEARCH [J].

FLEMING, TR ;

PRENTICE, RL ;

PEPE, MS ;

GLIDDEN, D .

STATISTICS IN MEDICINE, 1994, 13 (09) :955-968

[8] Surrogate end points in clinical trials: Are we being misled? [J].

Fleming, TR ;

DeMets, DL .

ANNALS OF INTERNAL MEDICINE, 1996, 125 (07) :605-613

[9]

Gail M H, 2000, Biostatistics, V1, P231, DOI 10.1093/biostatistics/1.3.231

[10]

Hill AM, 1998, ANTIVIR THER, V3, P139

← 1 2 →